A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how well a daily dose of 150 mg of Erivedge
(vismodegib) reduces Keratocystic odontogenic tumor (KCOT) size, and to evaluate the safety
of this dose. Erivedge is FDA-approved for use in adults with a specific type of skin cancer.
However, the drug is experimental for patients with KCOT.
Phase:
Phase 2
Details
Lead Sponsor:
NYU College of Dentistry The Bluestone Center for Clinical Research